Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib by Goldberg AS, Hegele RA

Get full text

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada by Lachaine J, Charron JN, Gregoire JC, Hegele RA, Leiter LA

Get full text

Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy by Roberts, JD, Murphy, NP, Hamilton, RM, Lubbers, ER, James, CA, Kline, CF, Gollob, MH, Krahn, AD, Sturm, AC, Musa, H, El-Refaey, M, Koenig, S, Aneq, MÅ, Hoorntje, ET, Graw, SL, Davies, RW, Rafiq, MA, Koopmann, TT, Aafaqi, S, Fatah, M, Chiasson, DA, Taylor, MRG, Simmons, SL, Han, M, Van Opbergen, CJM, Wold, LE, Sinagra, G, Mittal, K, Tichnell, C, Murray, B, Codima, A, Nazer, B, Nguyen, DT, Marcus, FI, Sobriera, N, Lodder, EM, Van Den Berg, MP, Spears, DA, Robinson, JF, Ursell, PC, Green, AK, Skanes, AC, Tang, AS, Gardner, MJ, Hegele, RA, Van Veen, TAB, Wilde, AAM, Healey, JS, Janssen, PML, Mestroni, L, Van Tintelen, JP, Calkins, H, Judge, DP, Hund, TJ, Scheinman, MM, Mohler, PJ

Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect by Tadros, R, Francis, C, Xu, X, Vermeer, AMC, Harper, AR, Huurman, R, Kelu Bisabu, K, Walsh, R, Hoorntje, ET, Te Rijdt, WP, Buchan, RJ, van Velzen, HG, van Slegtenhorst, MA, Vermeulen, JM, Offerhaus, JA, Bai, W, de Marvao, A, Lahrouchi, N, Beekman, L, Karper, JC, Veldink, JH, Kayvanpour, E, Pantazis, A, Baksi, AJ, Whiffin, N, Mazzarotto, F, Sloane, G, Suzuki, H, Schneider-Luftman, D, Elliott, P, Richard, P, Ader, F, Villard, E, Lichtner, P, Meitinger, T, Tanck, MWT, van Tintelen, JP, Thain, A, McCarty, D, Hegele, RA, Roberts, JD, Amyot, J, Dubé, M-P, Cadrin-Tourigny, J, Giraldeau, G, L'Allier, PL, Garceau, P, Tardif, J-C, Boekholdt, SM, Lumbers, RT, Watkins, H